03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
22:08 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Nimble move

Celgene Corp. ’s deal with Nimbus Therapeutics LLC is another vote of confidence that Nimbus’ computational drug design technology can solve druggability problems that trip up standard medicinal chemistry. The partnership gives Celgene access to...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
03:39 , Apr 22, 2017 |  BioCentury  |  Product Development

Playing JAKs

A desire to improve upon marketed autoimmune drug Xeljanz tofacitinib, coupled with interesting biological findings, led Pfizer Inc. to develop a portfolio of selective Janus kinase inhibitors that are taking the target into new disease...
19:14 , Jan 26, 2017 |  BC Innovations  |  Translation in Brief

Blanketly blocking MLL

Seven years after it discovered the unifying factor underlying the 70 seemingly unrelated translocations that all lead to mixed-lineage leukemia (MLL), a Northwestern team has devised a therapeutic strategy that could work across virtually all...
19:14 , Jan 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Leukemia Cell culture and mouse studies suggest inhibiting IRAK4 could help treat mixed-lineage leukemia (MLL). In HEK cells, shRNA targeting IRAK4 or an IRAK4 inhibitor tool compound increased the stability of wild-type MLL1 ,...
07:00 , Oct 10, 2016 |  BioCentury  |  Emerging Company Profile

Pellino play

Bridge Biotherapeutics Inc. has licensed the first of what it hopes will be many assets it can use its translational expertise to bring through Phase II proof of concept. The South Korean company is seeking...